Live-Attenuated Rift Valley Fever Virus Vaccination Leads to Durable, Protective Immunity Independent of Sex in C57BL/6 Mice
The Journal of Infectious Diseases · 15.10.2026 · 234 (4) · e812-e822
DOI: 10.1093/infdis/jiag266 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 15.05.2026. Verfasst von Karina Mueller Brown und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Rift Valley fever virus, Rift Valley Fever, Viral Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Operations of The University of Pittsburgh Regional Biocontainment Laboratory, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Rift Valley fever virus (RVFV) is a zoonotic arbovirus endemic to Africa and the Arabian Peninsula that can cause disease in humans and livestock. There are currently no licensed vaccines for human use, but several candidates are at the clinical trial, stage including DDVax™, a preparation of live-attenuated RVFV lacking the nonstructural proteins NSs and NSm (ΔNSsΔNSm). Multiple preclinical studies have shown that ΔNSsΔNSm is safe and immunogenic.
Methods
The longitudinal study described in this manuscript examined the additional features of duration, sex, and dose in immunogenicity and protection provided by ΔNSsΔNSm. Female and male 8-week-old C57BL/6 mice were vaccinated with either a low or high dose of ΔNSsΔNSm and humoral (via neutralization assay and enzyme-linked immunosorbent assay) and cellular immunity (enzyme-linked immunospot and flow cytometry) were assessed over a period of 6 months. A subset of animals was challenged with a lethal dose of wild-type RVFV 6 months postvaccination.
Results
All vaccinated animals were protected against lethal RVF disease 6 months postvaccination independent of dose or sex. Humoral immunity in the form of RVFV-specific neutralizing and binding antibodies decreased over time but remained detectable at the end of the study. The RVFV-specific CD4+ T cells also decreased by 6 months postvaccination. In contrast, virus-specific polyfunctional CD8+ T cells persisted at comparable levels throughout the study.
Conclusions
This work demonstrates that a single low-dose ΔNSsΔNSm vaccine elicits a durable humoral and cellular immune response that persists over months and protects C57BL/6 mice against lethal RVF disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.
- Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- One Health Institute, School of Veterinary Medicine, University of California, Davis, California, USA.
ORCID-Profile: Karina Mueller Brown, Tracey L Freeman, Dominique J Barbeau, Brian H Bird, Anita K McElroy
Förderung
- Operations of The University of Pittsburgh Regional Biocontainment Laboratory
- NIAID NIH HHS
- NIH HHS
- UPMC Children's Hospital of Pittsburgh
- Center for Vaccine Research
- National Institute of Allergy and Infectious Disease
- National Institutes of Health
Zitieren
APA
Mueller Brown, K., Kindsvogel, A. M., Petnuch, S. E., Freeman, T. L., Adam, N. E., Wilson, L. R., Xu, L., Barbeau, D. J., Bird, B. H., & McElroy, A. K. (2026). Live-Attenuated Rift Valley Fever Virus Vaccination Leads to Durable, Protective Immunity Independent of Sex in C57BL/6 Mice. The Journal of Infectious Diseases, 234(4), e812-e822. https://doi.org/10.1093/infdis/jiag266
Vancouver
Mueller Brown K, Kindsvogel AM, Petnuch SE, Freeman TL, Adam NE, Wilson LR, et al. Live-Attenuated Rift Valley Fever Virus Vaccination Leads to Durable, Protective Immunity Independent of Sex in C57BL/6 Mice. The Journal of Infectious Diseases. 2026;234(4):e812-e822. doi:10.1093/infdis/jiag266
BibTeX
@article{MuellerBrown2026,
author = {Mueller Brown, Karina and Kindsvogel, Angel M and Petnuch, Sarah E and Freeman, Tracey L and Adam, Nathan E and Wilson, Lindsay R and Xu, Lingqing and Barbeau, Dominique J and Bird, Brian H and McElroy, Anita K},
title = {Live-Attenuated Rift Valley Fever Virus Vaccination Leads to Durable, Protective Immunity Independent of Sex in C57BL/6 Mice},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {234},
number = {4},
pages = {e812--e822},
doi = {10.1093/infdis/jiag266}
}
EUVIMED